Voxelotor (Oxbryta)

From HemOnc.org - A Hematology Oncology Wiki
Revision as of 00:34, 31 March 2021 by Jwarner (talk | contribs) (Created page with "==Mechanism of action== hemoglobin S polymerization inhibitor ==Diseases for which it is used== *Sickle cell anemia ==History of changes in FDA indication== *11/25/2019:...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Mechanism of action

hemoglobin S polymerization inhibitor

Diseases for which it is used

History of changes in FDA indication

  • 11/25/2019: Granted accelerated approval for the treatment of sickle cell disease in adults and pediatric patients 12 years of age and older.
Retrieved from "https://hemonc.org/w/index.php?title=Voxelotor_(Oxbryta)&oldid=47979"